Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
RAPT Therapeutics (RAPT) hat sich auf Immunologie basierende Therapeutika spezialisiert. Im Fokus stehen orale Wirkstoffe für Patienten mit signifikant unerfüllten Bedürfnissen in entzündlichen Erkrankungen und Krebs. Seit der Gründung hat der Konzern zwei Wirkstoffkandidaten entdeckt und in die klinische Entwicklung vorangetrieben, von denen jeder CCR4 ins Visier nimmt. In einer randomisierten,...
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher...
The consensus price target hints at a 282.7% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective,...
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in...
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused...
